Trial reportBone marrow transplantation2017
Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.
Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.British journal of haematology · 2026Review
- Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy.Frontiers in immunology · 2026Review
- Article
- Immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells in patients with newly diagnosed multiple myeloma.Journal of medical biochemistry · 2025Article
- Identification and prognostic prediction of high-risk multiple myeloma by exosomal microRNA.Frontiers in oncology · 2025Article
- Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma.Molecular biology reports · 2024Review
- Article
- Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM.Blood advances · 2023Article
- Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma.International journal of molecular sciences · 2022Review
- Review
- Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement.PloS one · 2022Article
- Review
- Review
- Prognostic and predictive biomarker developments in multiple myeloma.Journal of hematology & oncology · 2021Review
- Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology-Highlights of the 8th Heidelberg Myeloma Workshop.Cancers · 2021Article
- Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications.Cancers · 2020Review
- Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.Leukemia · 2020Article
- Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches.Frontiers in oncology · 2020Review
- Article
- Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.